KDR and non-small cell lung carcinoma: Furthermore, inhibition of angiogenesis has been shown to confer a survival benefit in a phase III trial in non-small cell lung cancer (NSCLC).[8] VEGFR-2 is thought to provide both mitogenic and survival signals, and to be the major signaling component in angiogenesis.